Investing.com - Financial Markets Worldwide

AstraZeneca PLC ADR (AZN)

Symbol
Exchange
Currency
AZN
NASDAQUSDReal-time
AZNs
BATS EuropeSEKDelayed
AZNl
BATS EuropeGBPDelayed
AZNCF
OTC MarketsUSDDelayed
AZN
DerivedGBPReal-time
3SAZ
LondonGBPReal-time
3LAZ
LondonGBPReal-time
AZN
LondonGBPReal-time
AZNN
MexicoMXNDelayed
AZN
StockholmSEKReal-time
AZN
FrankfurtEURDelayed
AZNPy
FrankfurtEURDelayed
AZN
TradeGateEURDelayed
AZN
XetraEURDelayed
AZN
Buenos AiresARSDelayed
54.79
-0.09(-0.16%)
-Closed.
Currency in USD
Pre Market
54.40
-0.39(-0.71%)
- Real-time Data
  • Volume:
    5,349,874
  • Bid/Ask:
    54.40/54.43
  • Day's Range:
    54.67 - 55.42

AZN Overview

Prev. Close
54.88
Day's Range
54.67-55.42
Revenue
32.82B
Open
55.04
52 wk Range
46.49-64.21
EPS
0.63
Volume
5,349,874
Market Cap
168.5B
Dividend (Yield)
1.40
(2.55%)
Average Vol. (3m)
5,281,711
P/E Ratio
86.47
Beta
0.51
1-Year Change
2.62%
Shares Outstanding
1,549,158,964
Next Earnings Date
Feb 10, 2022
What is your sentiment on AstraZeneca PLC ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR News

AstraZeneca PLC ADR Analysis

AstraZeneca PLC ADR Company Profile

AstraZeneca PLC ADR Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
76100
Market
United States

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Income Statement

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellBuy
Technical IndicatorsSellStrong SellStrong SellStrong SellBuy
SummarySellStrong SellStrong SellStrong SellBuy

Trending Stocks

Trending Stocks

Name
Last
High
Low
Chg.
Chg. %
Vol.
Time
Apple
163.76164.20157.80-1.01-0.61%134.66MNASDAQ
Meta Platforms
310.39314.60307.20-0.21-0.07%24.19MNASDAQ
Alphabet A
2,859.302,877.302,804.30+38.3+1.36%1.45MNASDAQ
Merck&Co
73.8974.7873.30-0.55-0.74%15.28MNYSE
Nike
170.00170.54167.00+3.30+1.98%4.39MNYSE
IBM
116.90117.98116.56-0.02-0.02%5.26MNYSE
Salesforce.com
261.20262.58252.14+9.70+3.86%12.17MNYSE
Cisco
56.1556.6155.08+1.12+2.04%22.35MNASDAQ
3M
170.26172.78169.87-0.47-0.28%3.36MNYSE
Amazon.com
3,437.363,492.703,423.75-6.36-0.18%3.18MNASDAQ
Pfizer
53.0455.0852.77-1.64-3.00%46.17MNYSE
GameStop Corp
181.56187.43173.07+1.72+0.96%2.08MNYSE
NVIDIA
321.26324.78310.25+6.91+2.20%46.86MNASDAQ
Coinbase Global
284.71305.32283.82-9.79-3.32%4.56MNASDAQ
Corsair
21.7822.0321.02+0.44+2.06%1.19MNASDAQ
  • Valneva
    0
    • why this trash going up?
      1
      • already breakout guy.
        0
        • I would await some further drop based on the below article to come in the near future. The company did not perform well with the vaccine and i opened some short positions if my assumptions are correct.
          0
          • https://moneyweek.com/investments/stocks-and-shares/biotech-stocks/603675/astrazenecas-covid-troubles-could-see-it-pull
            0
            • hold long = big victory ✌
              0
              • Finally it reached $60+.
                0
                • AZN and MRK: Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. Support is strong for the 2 stocks.
                  0
                  • the Delta virus already in USA, but the CDC covered up the truth. in this next 2 weeks, millions of people will get infected, many states may lockdown again.
                    1
                    • Forget about AZN vaccines, they product it at no profit. The Company continues to engage with governments, international organisations and collaborators around the world to ensure broad and equitable access to this well-tolerated and effective vaccine at no profit during the pandemic period.
                      0
                      • The company has been doing a great job so far this year, will continue making profit from COVID-19 vaccines and many other drugs.
                        0
                        • Good news, AstraZeneca said the EU had lost its legal case, the company will deliver vaccines to EU.
                          0
                          • Wow, look at the hug volume, the long awaited $60 to come next week.
                            0
                            • the beginning of the end . the train pulls down.
                              0
                              • CBC News Canada: As per The National Advisory Committee on Immunization (NACI) in Canada announced, the people who took 1st dose of AstraZenaca, as 2nd dose they will take Pfizer-BioNTech COVID-19 Vaccine, or Moderna. Since early May, all provinces have halted the use of AstraZeneca for first doses.
                                0
                                • MOSCOW, June 17 (Reuters) - Moscow is facing a new coronavirus variant that is more aggressive and infectious, and the situation in the city is rapidly deteriorating, Moscow mayor, Sergei Sobyanin said.A new mutation has arrived, a new strain is active. It's more aggressive, it's harder to recover from, it spreads faster. It's much more likely to penetrate a person's immune system," Sobyanin said, according to the RIA news agency.
                                  0
                                  • EU to decide on Astrazeneca's $39 billion Alexion deal by July 5
                                    1
                                    • Once EU approves the deal, AZN will have 5 more profitable drugs to sell worldwide.
                                      1
                                  • AZN vaccines work very well in India and Japan .
                                    1
                                    • AZN Vaccine halted in Italy due to a teenager’s death.
                                      0
                                      • UK study finds AZN vaccines offer 92% protection against hospitalisation from Delta variant
                                        1
                                        • Look at the Gaps, enjoy the speed.
                                          1
                                          • let's go baby, up up & away
                                            1
                                            • all vaccines are effective, experts point out that their efficacy wanes over time, and a booster dose may be needed every year. The company will make profits from Covid-19 vaccines every year.
                                              2
                                              • There is global shortage of coronavirus vaccines, WHO approved AZN vaccine for Emergency Use.
                                                1
                                                • We need to trust scientists, US government and WHO.
                                                  3
                                              • Three speculative pumps a while ago. Be careful. This position is short
                                                0
                                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.